Half Year Presentation 2021

Improving Global Animal Health and Welfare

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide.

Our Purpose is the sustainable improvement of global animal health and welfare.

For more information please visitwww.dechra.com

Companion Animal Products (CAP)

Species: Dogs and cats.

Key therapeutic sectors: Endocrinology, dermatology, analgesia and anaesthesia, antibiotics, cardiovascular and critical care.

Food producing Animal Products (FAP)

Species: Poultry, pigs and an increasing presence in cattle.

Key therapeutic sectors: Water soluble antibiotics, poultry vaccines, locomotion (lameness) and pain management.

Nutrition

Species: Dogs and cats.

Species: Dogs and cats.

Key therapeutic sectors: Our pet diets are available to support the wellbeing of cats and dogs with numerous therapeutic conditions, such as allergies, obesity, heart and kidney disease.

We continue to function and be effective throughout COVID-19

Portfolio Focus

  • • Strong market dynamics

  • • All product categories delivering double digit growth

Pipeline Delivery

  • • Good progress continues

  • • Akston proof of concept studies continue to show favourable results

Geographic Expansion

  • • Brazil and ANZ performing well

  • • Robust performance from distribution business

Acquisition

  • • Osurnia and Mirataz performing ahead of expectations

  • • European launch of Mirataz imminent

  • • Tri-Solfen for ANZ

Strategic Enablers

Technology

  • • Focus on remote working capabilities and digital communication

  • • Key ancillary system roll outs underway and on track

Manufacturing and Supply

  • • Majority of historic supply issues resolved

  • • Further investment to strengthen quality systems

  • • Significant expansion of Danish distribution centre underway

People

  • • Commitment and dedication of all employees has been exceptional

  • • Significant progress on actioning Dechra's pay principles, particularly 'Living Wage'

  • • Employee Engagement

Environmental, Social and Governance

  • • Focus on gathering data and establishing targets

  • • Group Sustainability Director appointed and will be in role from 1 March

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Dechra Pharmaceuticals plc published this content on 24 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 February 2021 09:03:04 UTC.